Insomnia, Sleep Quality, and Quality of Life in Mild to Moderate Parkinson’s Disease

Shafazand, Shirin; Wallace, Douglas M.; Arheart, Kristopher L.; Vargas, Silvia; Luca, Corneliu; Moore, Henry; Katzen, Heather; Levin, Bonnie; Singer, Carlos

doi:10.1513/annalsats.201608-625oc

Cited by 35 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering non-motor symptoms, sleep is evaluated in 11 studies, predominantly using wearable devices. This patient-relevant [108] 'outcome' in PD is very complicated with various sleep diagnoses being more common in the PD population (e.g., REM sleep behaviour disorder, restless legs syndrome, insomnia) [109]. Other non-motor outcomes remain largely unmeasured in the home environment.…”

Section: What Is Being Measured?mentioning

confidence: 99%

Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment

Morgan

Rolinski

McNaney

et al. 2020

JPD

View full text Add to dashboard Cite

Background: The emergence of new technologies measuring outcomes in Parkinson's disease (PD) to complement the existing clinical rating scales has introduced the possibility of measurement occurring in patients' own homes whilst they freely live and carry out normal day-today activities. Objective: This systematic review seeks to provide an overview of what technology is being used to test which outcomes in PD from free-living participant activity in the setting of the home environment. Additionally, this review seeks to form an impression of the nature of validation and clinimetric testing carried out on the technological device(s) being used. Methods: Five databases (Medline, Embase, PsycInfo, Cochrane and Web of Science) were systematically searched for papers dating from 2000. Study eligibility criteria included: adults with a PD diagnosis; the use of technology; the setting of a home or home-like environment; outcomes measuring any motor and non-motor aspect relevant to PD, as well as activities of daily living; unrestricted/unscripted activities undertaken by participants.

show abstract

Section: What Is Being Measured?mentioning

confidence: 99%

Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment

Morgan

Rolinski

McNaney

et al. 2020

JPD

View full text Add to dashboard Cite

show abstract

“…Surveys suggest that insomnia affects 46% of PD patients; vivid dreams, 34%; acting out while dreaming, 36%; and restless legs syndrome, 42% . Depression, anxiety, cognitive problems, stress, and daytime sleepiness have been found to result from these conditions, and sleep disorders in PD have a negative impact on patients’ quality of life (QoL) …”

Section: Introductionmentioning

confidence: 99%

“…1 Depression, anxiety, cognitive problems, stress, and daytime sleepiness have been found to result from these conditions, and sleep disorders in PD have a negative impact on patients' quality of life (QoL). 9,10 On the other hand, using the King's Parkinson's Disease Pain Scale (KPPS), 11 the syndromic nature of pain has been formally subdivided into several patterns. Prior research has shown that the prevalence of pain is 68 to 81% in PD patients [12][13][14] and that it can be manifested in several modalities, such as musculoskeletal (41-89%), dystonic (15-17%), radicular-neuropathic (27-32%), and central pain (4-22%).…”

Section: Introductionmentioning

confidence: 99%

Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease

Martinez‐Martín

Rizos

Wetmore

et al. 2018

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Little research has been conducted regarding the relationship between sleep disorders and different pain types in Parkinson's disease (PD). Objective To explore the influence of the various pain subtypes experienced by PD patients on sleep. Methods Three hundred consecutive PD patients were assessed with the PD Sleep Scale‐Version 2 (PDSS‐2), King's PD Pain Scale (KPPS), King's PD Pain Questionnaire (KPPQ), Visual Analog Scales for Pain (VAS‐Pain), and Hospital Anxiety and Depression Scale. Results According to the PDSS‐2, 99.3% of our sample suffered from at least one sleep issue. Those who reported experiencing any modality of pain suffered significantly more from sleep disorders than those who did not (all, P < 0.003). The PDSS‐2 showed moderate‐to‐high correlations with the KPPS (rS = 0.57), KPPQ (0.57), and VAS‐Pain (0.35). When PDSS‐2 items 10 to 12 (pain‐related) were excluded, the correlation values decreased to 0.50, 0.51, and 0.28, respectively, while these items showed moderate‐to‐high correlations with KPPS (0.56), KPPQ (0.54), and VAS‐Pain (0.42). Among the variables analyzed, multiple linear regression models suggested that KPPS and KPPQ were the most relevant predictors of sleep disorders (as per the PDSS‐2), although following exclusion of PDSS‐2 pain items, depression was the relevant predictor. Depression and anxiety were the most relevant predictors in the analysis involving the VAS‐Pain. Regression analysis, considering only the KPPS domains, showed that nocturnal and musculoskeletal pains were the best predictors of overall nocturnal sleep disorder. Conclusions Pain showed a moderate association with nocturnal sleep dysfunction in PD. Some pain subtypes had a greater effect on sleep than others.

show abstract

“…Sleep dysfunction is prominent across the spectrum of neurodegenerative conditions, occurring in 40 to 0% of patients [1][2][3][4][5]. It is a key determinant of patients' quality of life [6], falls risk [7], and progression to institutionalization [8][9][10][11], as well as caregiver burden and health [12][13][14]. It should therefore be a priority in the clinical care of patients with neurodegenerative disease but is currently typically overlooked.…”

Section: Introductionmentioning

confidence: 99%

The Treatment of Sleep Dysfunction in Neurodegenerative Disorders

2021

View full text Add to dashboard Cite

Sleep dysfunction is highly prevalent across the spectrum of neurodegenerative conditions and is a key determinant of quality of life for both patients and their families. Mounting recent evidence also suggests that such dysfunction exacerbates cognitive and affective clinical features of neurodegeneration, as well as disease progression through acceleration of pathogenic processes. Effective assessment and treatment of sleep dysfunction in neurodegeneration is therefore of paramount importance; yet robust therapeutic guidelines are lacking, owing in part to a historical paucity of effective treatments and trials. Here, we review the common sleep abnormalities evident in neurodegenerative disease states and evaluate the latest evidence for traditional and emerging interventions, both pharmacological and nonpharmacological. Interventions considered include conservative measures, targeted treatments of specific clinical sleep pathologies, established sedating and alerting agents, melatonin, and orexin antagonists, as well as bright light therapy, behavioral measures, and slow-wave sleep augmentation techniques. We conclude by providing a suggested framework for treatment based on contemporary evidence and highlight areas that may emerge as major therapeutic advances in the near future.

show abstract

Insomnia, Sleep Quality, and Quality of Life in Mild to Moderate Parkinson’s Disease

Cited by 35 publications

References 28 publications

Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment

Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment

Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease

The Treatment of Sleep Dysfunction in Neurodegenerative Disorders

Contact Info

Product

Resources

About